|FOR IMMEDIATE RELEASE
Tuesday, April 4, 2000
Contact: Alison Davis (NIGMS)|
First Awards Made in NIH Effort to Understand How Genes Affect People's Responses to Medicines
- Stanford University School of Medicine in Palo Alto, Calif. (Russ B. Altman, M.D., Ph.D., principal investigator) $1.6 million provided by NIGMS, NHGRI, and NLM to house and operate the Stanford Pharmacogenetics Knowledge Base (PharmGKB), which will serve as the shared information library for all scientists in the pharmacogenetics research network.]
- Brigham and Women's Hospital in Boston, Mass. (Jeffrey M. Drazen, M.D., principal investigator) $2.6 million provided by NHLBI for a multicenter effort to discover which genes play a role in people's widely variable responses to the three main types of asthma treatments.
- Georgetown University Medical Center in Washington, D.C. (David A. Flockhart, M.D., Ph.D., principal investigator) $1.3 million provided by NIGMS to investigate if and how genetic differences between people can explain the variable responses to tamoxifen, a widely prescribed drug used for cancer treatment and prevention.
- University of California, San Francisco (Kathleen M. Giacomini, Ph.D., principal investigator) $3.2 million provided by NIGMS to study how drug response is affected by variability in the genes that encode cellular "gatekeeper" molecules called membrane transporters, which interact with a third of the most commonly used prescription drugs.
- University of California, Los Angeles (Julio Licinio, M.D., principal investigator) $285,000 provided by NIGMS for a one-year pilot project to search for genetic differences that play a role in how Mexican-Americans respond to two different antidepressant drugs.
- Yale University in New Haven, Conn. (Prakash M. Nadkarni, M.D., principal investigator) $421,000 provided by NIEHS to develop and implement a Web-based database tool designed to incorporate existing pharmacogenetic knowledge into the PharmGKB information library.
- University of Chicago (Mark J. Ratain, M.D., principal investigator) $2.5 million provided by NIGMS and NCI for a multicenter effort to examine how the benefits, as well as the toxic side effects, of certain chemotherapy drugs vary among people.
- University of Houston Law Center in Houston, Tex. (Mark A. Rothstein, J.D., principal investigator) $322,000 provided by NIGMS, NHGRI, and NIEHS to study the ethical, legal, and social implications of the use of pharmacogenetic information, paying particular attention to issues of race and ethnicity.
- The Mayo Foundation in Rochester, Minn. (Richard M. Weinshilboum, M.D., principal investigator) $576,000 provided by NIGMS and NHGRI to exhaustively search for variations in genes encoding proteins already known to be important in the body's handling and disposal of a wide array of medicines, hormones, and chemical messengers.
NIH has announced its intent to solicit applications for the next round of pharmacogenetics research network awards. Applicants who devise the best plans for conducting pharmacogenetics research that will complement existing studies will join the network, and will contribute to the PharmGKB information library.
NIGMS funds research and research training in the basic biomedical sciences, including pharmacology, cell and molecular biology, and genetics. This support enables scientists at universities, medical schools, and research institutions throughout the country to expand knowledge about the fundamental life processes that underlie human health and disease.
To arrange an interview with Dr. Rochelle Long, please contact Alison Davis at 301/496-7301.